Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives from a large internet forum
Open accessThe DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index; 29 of the 107 sources its claims cite were checked for support.
Abstract
Background: Protracted withdrawal syndrome (PWS) after stopping antidepressants (frequently also referred to as post-acute withdrawal syndrome or PAWS) has been described in a few case reports. However, a detailed quantitative analysis of specific symptom manifestations in antidepressant PWS is still lacking. Methods: We extracted patient narratives from a large English-language internet forum SurvivingAntidepressants.org , a peer support site concerned about withdrawal from antidepressants. PWS was ascertained based on diagnostic criteria proposed by Chouinard and Chouinard, specifically ⩾6 months of continuous antidepressant use, with emergence of new and/or more intense symptoms after discontinuation that last beyond the initial 6 weeks of acute withdrawal. We assessed medication history, outcome of PWS, and the prevalence of specific symptoms. Results: In total, n = 69 individual reports of protracted withdrawal were selected for analysis. At time of the subjects’ most recent reports, duration of PWS ranged from 5 to 166 months, mean = 37 months, median = 26 months. Length of time on the antidepressant causing protracted withdrawal ranged from 6 to 278 months, mean = 96 months, and median = 79 months. Throughout the withdrawal experience, affective symptoms, mostly anxiety, depression, emerging suicidality and agitation, were reported by 81%. Somatic symptoms, mostly headache, fatigue, dizziness, brain zaps, visual changes, muscle aches, tremor, diarrhea, and nausea were reported by 75%. Sleep problems (44%) and cognitive impairments (32%) were mentioned less frequently. These broad symptom domains were largely uncorrelated. Conclusion: PWS or PAWS from antidepressants can be severe and long-lasting, and its manifestations clinically heterogeneous. Long-term antidepressant exposure may cause multiple body system impairments. Although both somatic and affective symptoms are frequent, they are mostly unrelated in terms of occurrence. Proper recognition and detection of PWS thus requires a comprehensive assessment of medication history, duration of the withdrawal syndrome, and its various somatic, affective, sleep, and cognitive symptoms.
Overview
CoChat Summary
TL;DR
In 69 consumer narratives meeting proposed criteria for protracted withdrawal syndrome (PWS) after stopping antidepressants, symptoms were severe, clinically heterogeneous, and often long-lasting, with PWS duration ranging from 5 to 166 months. Affective and somatic symptoms were the most common but largely uncorrelated, suggesting PWS requires broad assessment across symptom domains.
Key findings
- Among 69 PWS cases, duration of PWS at last report ranged from 5 to 166 months (mean = 37, median = 26), and time on the implicated antidepressant ranged from 6 to 278 months (mean = 96, median = 79).
- Affective symptoms were reported by 81% (abstract; 82.6% in results), most commonly anxiety (64.9%), depression (43.9%), and emerging suicidality (24.6%); somatic symptoms were reported by 75% (abstract; grouped somatic syndrome 73.9% in results), most commonly headache, fatigue, dizziness, brain zaps, visual changes, muscle aches, tremor, diarrhea, and nausea.
- Sleep problems were reported by 44% and cognitive impairments by 32%; broad symptom domains were largely uncorrelated, with somatic and affective symptoms weakly associated (r = 0.16, p = 0.18).
- Reinstatement of the suspected antidepressant resolved PWS in 9 of 19 who attempted it; 2 subjects died by suicide, and more than one-third were lost to follow-up.
Methods
- The authors extracted 94 pseudonymous patient narratives tagged as potential PWS from SurvivingAntidepressants.org, then applied Chouinard and Chouinard criteria: continuous antidepressant use for at least 6 months and withdrawal symptoms persisting beyond 6 weeks, with new or more intense symptoms; 25 reports were excluded, leaving n = 69.
- One author coded medication history, PWS outcome, and symptom presence/quality using Fava et al.’s symptom classification; coding was cross-validated by a second author, with discrepancies resolved by consensus.
- Analyses were descriptive, with Pearson correlations/phi coefficients and 95% CIs computed via bias-corrected and accelerated bootstrapping based on 5000 samples; no correction for multiple testing was applied because analyses were exploratory.
Limitations
- The paper states the sample was modest (n = 69), lacked power to analyze individual drugs or drug classes, and relied on spontaneous self-reports that were neither systematically assessed nor clinically validated; reported symptom rates are therefore likely conservative underestimates.
- The authors note possible misattribution of symptoms to antidepressant withdrawal rather than mental disorder or undiagnosed medical condition, and their semantic analysis could not distinguish PWS-induced affective symptoms from emotional reactions to debilitation or true relapse.
- The text also makes evident that age and gender could not be assessed consistently, eight cases involved discontinuation among other drugs with sometimes unclear timelines, and more than one-third of subjects were lost to follow-up, leaving PWS outcome unknown for many.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
9 Valid · 3 Not valid · 31 Not checked · 82 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“In this respect, antidepressants do not differ from other dependence-forming central nervous system (CNS) drugs like benzodiazepines, opioids, gabapentinoids, or psychostimulants.3,19–22”
§ Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives from a large internet forum > Introduction
What the sources say
- Disputedcites [3] Marsden J White M Annand F, et al Medicines associated with dependence or withdrawal: a mixed-methods public health review and national database study in England. Lancet Psychiatry 2019; 6: 935– 950. 31588045 PMC7029276 sourceExperimental — accuracy not yet measured
Our copy says the opposite of the claim on dependence: the Introduction states 'Antidepressants are not associated with a risk of dependence', and the Discussion repeats 'Although antidepressants are not associated with dependence...' while noting only withdrawal symptoms on discontinuation (placebo-controlled trial evidence of withdrawal syndrome, dizziness, etc.). The Discussion also explicitly contrasts antidepressants with the other classes ('The situation is different with antidepressants... long-term prescribing... is indicated for many people with severe depression'). Furthermore, the study's scope covers antidepressants, opioids for non-cancer pain, gabapentinoids, benzodiazepines and Z-drugs only — psychostimulants are not examined, so no comparison of propensity to dependence and withdrawal across those drug classes is made anywhere in our copy. (LLM, conf=0.85)
Checked by a reasoning model — may be wrong.
- Partly supportedcites [19] Cosci F Chouinard G. Acute and persistent withdrawal syndromes following discontinuation of psychotropic medications. Psychother Psychosom 2020; 89: 283– 306. 32259826 sourceExperimental — accuracy not yet measured
The Diagnostic criteria section (p. 2) states that for SSRIs/SNRIs the term 'withdrawal syndrome' is appropriate and 'there are no reasons to believe that there are differences from other classes of psychotropic drugs', and the Abstract (p. 1) rejects the belief that benzodiazepines should be replaced by 'medications that cause less dependence such as antidepressants' — this supports the claim's core for benzodiazepines, and gabapentin is listed among the withdrawal-associated classes (p. 2). However, the paper's declared scope is psychotropic medications only (benzodiazepines, Z-drugs, antidepressants, ketamine, antipsychotics, lithium, mood stabilizers; Introduction/aim, pp. 1-2), and no passage in our copy addresses opioids or psychostimulants, so those comparators in the claim are not supported by this source. The Discussion (p. 16) also qualifies the equivalence: 'not all psychotropic medications are the same between classes and within a class', with SSRIs/SNRIs/antipsychotics consistently linked to persistent post-withdrawal disorders whereas benzodiazepine distress is described as short-lived (Abstract, p. 1). (LLM, conf=0.78)
- Partly supportedcites [20] Lerner A Klein M. Dependence, withdrawal and rebound of CNS drugs: an update and regulatory considerations for new drugs development. Brain Commun 2019; 1: fcz025. PMC7425303 32954266 sourceExperimental — accuracy not yet measured
Our copy supports the shared-feature part: the Definitions section (Part I) states that 'dependence and withdrawal' 'potentially may encompass all drug classes, because it may be viewed as a function of an organism's adaptation to the presence of a drug,' and Part II lists antidepressants (SSRIs/SNRIs, tricyclics) and gabapentin alongside opioids, benzodiazepines and stimulants as drug classes with well-known withdrawal syndromes. It does not support the claim's core assertion that antidepressants 'do not differ ... in their propensity': the Introduction places antidepressants among 'other drug classes generally not associated with abuse and not scheduled under the Controlled Substances Act,' the Factors influencing formation of drug dependence section says 'Opiate, GABA-ergic and dopaminergic systems tend to be more frequently linked to the development of dependence,' and the Summary points single out opioids as having 'the shortest known time to acquire dependence' (2-3 weeks). So the equivalence-of-propensity element attributed to this source is not in it, and the paper in fact marks differences between these classes. (LLM, conf=0.72)
- Not checked yetcites [21] Nielsen M Hansen EH Gotzsche PC. What is the difference between dependence and withdrawal reactions? A comparison of benzodiazepines and selective serotonin re-uptake inhibitors. Addiction 2012; 107: 900– 908. 21992148 source
- Not checked yetcites [22] Baldessarini RJ Tondo L. Effects of treatment discontinuation in clinical psychopharmacology. Psychother Psychosom 2019; 88: 65– 70. 30923289 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“The narratives analyzed in this study likewise indicate that consumers are able to distinguish drug withdrawal from the symptoms of the original illness, since withdrawal symptoms are experienced as more intense, urgent, and often unprecedented, that is, qualitatively different.28,30,35”
§ Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives from a large internet forum > Discussion > Summary and interpretation
What the sources say
- Partly supportedcites [28] Haddad PM Anderson IM. Recognising and managing antidepressant discontinuation symptoms. Adv Psychiatr Treat 2007; 13: 447– 457. sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Not checked yetcites [30] Fava GA Cosci F. Understanding and managing withdrawal syndromes after discontinuation of antidepressant drugs. J Clin Psychiatry 2019; 80: 19com12794. 31774947 source
- Disputedcites [35] Chouinard G Chouinard VA. New classification of selective serotonin reuptake inhibitor withdrawal. Psychother Psychosom 2015; 84: 63– 71. 25721565 sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 1 partially supported, 1 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Checked by a reasoning model — may be wrong.
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A possible driver of unnecessary long-term medication could be the propensity of antidepressants to cause physical dependence (i.e., pharmacodynamic neurophysiological adaptations) and withdrawal symptoms upon dose reduction or cessation discouraging discontinuation.11–18”
§ Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives from a large internet forum > Introduction
What the sources say
- Not checked yetcites [11] Kotzalidis GD Patrizi B Caltagirone SS, et al The adult SSRI/SNRI withdrawal syndrome: a clinically heterogeneous entity. Clin Neuropsychiatry 2007; 4: 61– 75.
- Partly supportedcites [12] Davies J Read J. A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: are guidelines evidence-based? Addict Behav 2019; 97: 111– 121. 30292574 sourceExperimental — accuracy not yet measured
The Conclusion (section 6) suggests that underestimated withdrawal reactions may prolong antidepressant use, including when symptoms are mistaken for relapse and medication is reinstated. The Limitations (section 5) discusses possible dependence but calls for further research; the copy does not establish the sentence’s specific explanation of physical dependence as pharmacodynamic neurophysiological adaptations. (LLM, conf=0.83)
- Partly supportedcites [13] Fava GA Gatti A Belaise C, et al Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review. Psychother Psychosom 2015; 84: 72– 81. 25721705 sourceExperimental — accuracy not yet measured
The Introduction and Discussion report withdrawal symptoms after SSRI cessation or gradual tapering, and the Discussion notes that persistent, distressing symptoms may lead to reinstating the antidepressant. But the paper does not establish that withdrawal discourages discontinuation or drives unnecessary long-term medication; it also describes the proposed physiological mechanisms as hypothetical. (LLM, conf=0.82)
- Partly supportedcites [14] Fava GA Benasi G Lucente M, et al Withdrawal symptoms after serotonin-noradrenaline reuptake inhibitor discontinuation: systematic review. Psychother Psychosom 2018; 87: 195– 203. 30016772 sourceExperimental — accuracy not yet measured
The Introduction (p. 1) reports withdrawal symptoms after antidepressant dose reduction or discontinuation, and the Discussion (pp. 6–7) describes dependence-and-withdrawal phenomena and says reintroducing an SNRI may relieve symptoms. The review focuses on SNRIs; it does not establish that withdrawal discourages discontinuation or drives unnecessary long-term medication. (LLM, conf=0.84)
- Partly supportedcites [15] Hengartner MP Davies J Read J. Antidepressant withdrawal - the tide is finally turning. Epidemiol Psychiatr Sci 2019; 29: e52. 31434594 PMC8061160 sourceExperimental — accuracy not yet measured
The Abstract (page not provided) says antidepressants can cause withdrawal on discontinuation, especially after prolonged use, and reports that trials often failed to withdraw long-term users despite gradual tapers. It also says withdrawal effects may lead clinicians to inappropriately continue prescriptions. The copy does not establish the citing sentence’s more specific characterization of physical dependence as pharmacodynamic neurophysiological adaptations. (LLM, conf=0.83)
- Supportedcites [16] Massabki I Abi-Jaoude E. Selective serotonin reuptake inhibitor ‘discontinuation syndrome’ or withdrawal. Br J Psychiatry. Epub ahead of print 6 January 2020. DOI: 10.1192/bjp.2019.269. 31902371 source
The Abstract says SSRI withdrawal symptoms can prolong antidepressant use because patients may experience intolerable symptoms when trying to stop. The Discussion states that SSRI use can result in dependence and withdrawal, and the section on defining discontinuation syndrome describes symptoms after dose reduction as well as cessation. Page numbers are not available in our copy. (LLM, conf=0.92)
- Not checked yetcites [17] Read J Cartwright C Gibson K. How many of 1829 antidepressant users report withdrawal effects or addiction? Int J Ment Health Nurs 2018; 27: 1805– 1815. 29873165 source
- Supportedcites [18] Horowitz MA Taylor D. Tapering of SSRI treatment to mitigate withdrawal symptoms. Lancet Psychiatry 2019; 6: 538– 546. 30850328 source
In the section labeled Abstract (page unavailable), the paper says withdrawal symptoms can be mistaken for depressive recurrence, prolonging treatment for patients who may not need it. It also says patients’ unwillingness to stop because withdrawal is aversive contributes to long-term SSRI use. Its discussion of receptor adaptation and withdrawal supports the claim’s description of physical dependence. (LLM, conf=0.93)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“But, as others have suspected,11,36 an antidepressant’s half-life probably is not a primary risk factor for PWS.”
§ Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives from a large internet forum > Discussion > Summary and interpretation
What the sources say
- Not checked yetcites [11] Kotzalidis GD Patrizi B Caltagirone SS, et al The adult SSRI/SNRI withdrawal syndrome: a clinically heterogeneous entity. Clin Neuropsychiatry 2007; 4: 61– 75.
- Partly supportedcites [36] Renoir T. Selective serotonin reuptake inhibitor antidepressant treatment discontinuation syndrome: a review of the clinical evidence and the possible mechanisms involved. Front Pharmacol 2013; 4: 45. 23596418 PMC3627130 sourceExperimental — accuracy not yet measured
In the Clinical Evidence section our copy does carry the sceptical core of the claim: after noting that discontinuation symptoms are more frequent after abrupt cessation of shorter half-life SSRIs, it states 'that relationship may not be an absolute predictor,' citing that paroxetine and fluvoxamine have similar half-lives yet fluvoxamine's withdrawal-reaction rate is 10 times lower, and that the paroxetine excess 'is likely to reflect the greater prescription rate' with 'other factors (i.e., pharmacological)' also contributing. The Discussion adds that 'it is currently unclear as to whether the discontinuation syndrome is equally related to the pharmacological properties of a given SSRI, and/or its half-life.' However, the review never concludes that half-life is not a primary risk factor — it affirms a half-life dependence (e.g., the longer half-lives of fluoxetine/sertraline active compounds 'may be the reason underlying fewer symptoms') and frames the issue as unresolved rather than discounted; it also restricts this to SSRIs, whereas the citing sentence generalises to 'an antidepressant.' The hedged attribution ('probably is not a primary risk factor') therefore overstates what this source says. (LLM, conf=0.68)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Thus, patients and prescribers may misattribute withdrawal symptoms as relapse or emergence of new mental disorders.11,16,21”
§ Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives from a large internet forum > Introduction
What the sources say
- Not checked yetcites [11] Kotzalidis GD Patrizi B Caltagirone SS, et al The adult SSRI/SNRI withdrawal syndrome: a clinically heterogeneous entity. Clin Neuropsychiatry 2007; 4: 61– 75.
- Partly supportedcites [16] Massabki I Abi-Jaoude E. Selective serotonin reuptake inhibitor ‘discontinuation syndrome’ or withdrawal. Br J Psychiatry. Epub ahead of print 6 January 2020. DOI: 10.1192/bjp.2019.269. 31902371 sourceExperimental — accuracy not yet measured
The Discussion (pp. 168–171) warns that SSRI withdrawal symptoms should not simply be assumed to be relapse. The section ‘Distinguishing discontinuation syndrome from withdrawal’ also describes concern that the terminology associates withdrawal with a disorder, but the paper does not specifically say that patients or prescribers mistake it for the emergence of new mental disorders. (LLM, conf=0.86)
- Not checked yetcites [21] Nielsen M Hansen EH Gotzsche PC. What is the difference between dependence and withdrawal reactions? A comparison of benzodiazepines and selective serotonin re-uptake inhibitors. Addiction 2012; 107: 900– 908. 21992148 source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
60 more claims · 1 with their cited sources checked
Create a free account to see all 125 claims and to verify the 78 references still open.
- Probably not a substantial claim. 33
- It may state two separate claims as one. 39
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Indeed, the whole concept of ‘regular tapering’ does not appear to exist as the current practice is that patients and doctors are improvising in a variety of patient- and doctor-specific ways to facilitate the tapering of medication in patients experiencing significant withdrawal.3”
From Successful use of tapering strips for hyperbolic reduction of antidepressant dose: a cohort study (2021) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Post-acute withdrawal or protracted withdrawal syndromes from antidepressants can be severe and long-lasting, and its manifestations clinically heterogeneous.3”
From Successful use of tapering strips for hyperbolic reduction of antidepressant dose: a cohort study (2021) · cites this paper as [3]
In the citing paper
“However, such a comparison is problematic as currently no definition exists of what would constitute ‘regular tapering’ and it is not known how to accommodate extensive patient heterogeneity in how medication reduction is best titrated against severity of withdrawal.”
From Successful use of tapering strips for hyperbolic reduction of antidepressant dose: a cohort study (2021) · cites this paper as [3]
Citations
Cites
Carvalho, A. F., Sharma, M. S., Brunoni, A. R., Vieta, E., & Fava, G. A. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000447034 · Cited by 650
Narrative based medicine: Narrative based medicine in an evidence based world
Greenhalgh, T. (1999) · BMJ · doi:10.1136/bmj.318.7179.323 · Cited by 518
Antidepressant use in persons aged 12 and over: United States, 2005-2008.
Pratt, L. A., Brody, D. J., & Gu, Q. (2011) · PubMed · Cited by 490
Initiation and adaptation: a paradigm for understanding psychotropic drug action
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.2.151 · Cited by 490
Fava, G. A., Gatti, A., Belaise, C., Guidi, J., & Offidani, E. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000370338 · Cited by 436
REVIEW: Acute withdrawal, protracted abstinence and negative affect in alcoholism: are they linked?
Heilig, M., Egli, M., Crabbe, J. C., & Becker, H. C. (2010) · Addiction Biology · doi:10.1111/j.1369-1600.2009.00194.x · Cited by 435
Influences on antidepressant prescribing trends in the UK: 1995–2011
Mars, B., Heron, J., Kessler, D., Davies, N. M., Martin, R. M., Thomas, K. H., & Gunnell, D. (2017) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-016-1306-4 · Cited by 419
Davies, J., & Read, J. (2019) · Addictive Behaviors · doi:10.1016/j.addbeh.2018.08.027 · Cited by 387
Emotional side-effects of selective serotonin reuptake inhibitors: qualitative study
Price, J., Cole, V., & Goodwin, G. M. (2009) · British Journal of Psychiatry · doi:10.1192/bjp.bp.108.051110 · Cited by 362
Addiction and dependence in DSM‐V
O'Brien, C. (2011) · Addiction · doi:10.1111/j.1360-0443.2010.03144.x · Cited by 292
Research works printed but not linked: 3
- Kotzalidis GD, 2007, Clin Neuropsychiatry, 4, 61
- Schatzberg AF, 1997, J Clin Psychiatry, 58, 5
- Becker HC., 2008, Alcohol Res Health, 31, 348
Cited by
den Eynde, V. V., Abdelmoemin, W. R., Abraham, M. M., Amsterdam, J. D., Anderson, I. M., Andrade, C., Baker, G. B., Beekman, A. T. F., Berk, M., Birkenhäger, T. K., et al. (2022) · CNS Spectrums · doi:10.1017/s1092852922000906 · Cited by 92
Dietch, D., Kerr‐Gaffney, J., Hockey, M., Marx, W., Ruusunen, A. A., Young, A. H., Berk, M., & Mondelli, V. (2023) · BJPsych Open · doi:10.1192/bjo.2023.36 · Cited by 85
Estimating Risk of Antidepressant Withdrawal from a Review of Published Data
Horowitz, M. A., Framer, A., Hengartner, M. P., Sørensen, A., & Taylor, D. (2023) · CNS Drugs · doi:10.1007/s40263-022-00960-y · Cited by 76
“Other studies also report longer durations of withdrawal symptoms, in at least some cases, symptoms can persist for years [13, 50, 54].”
BackgroundSelf-citation(2022) · doi:10.1192/bja.2021.62 · Cited by 73
Framer, A. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125321991274 · Cited by 73
Self-citation
Metadata
- Authors
- Hengartner, M. P., Schulthess, L., Sorensen, A., & Framer, A.
- Affiliations
- University of Zurich (CH)
- ZHAW Zurich University of Applied Sciences (CH)
- Nordic Cochrane Centre, Rigshospitalet, Copenhagen, Denmark
- Corresponding author
- Hengartner, Michael P.
- Venue
- Therapeutic Advances in Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2020-01
- Volume
- 10
- Pages
- 2045125320980573-2045125320980573
- ISSN
- 2045-1253 (ISSN-L)
- 2045-1261
- PMC
- PMC7768871
- OpenAlex
- W3115093202
- Semantic Scholar
- bc5b8e1948c66344be70291fe0ca65b5d0c05c92
- Cited by
- 74
- References
- 72
- Citations by year
- 2026: 21 · 2025: 8 · 2024: 10 · 2023: 6 · 2022: 18 · 2021: 11
- FWCI
- 5.24
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Therapeutic Advances in Psychopharmacology (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Zürcher Hochschule für Angewandte Wissenschaften digital collection (Zurich University of Applied Sciences) (submittedVersion, cc-by-nc-nd)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- ZHAW Digital Collection (cc-by-nc)
- Funders
- Stefan Hearst (na)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- antidepressant discontinuation, patient narratives, online forums, peer support, somatic symptoms, affective symptoms, anxiety, depression, suicidality, sleep disorders, cognitive impairment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives from a large internet forum. https://app.cochat.ai/papers/10.1177/2045125320980573
- The paper
- Hengartner, M. P., Schulthess, L., Sorensen, A., & Framer, A. (2020). Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives from a large internet forum. Therapeutic Advances in Psychopharmacology. https://doi.org/10.1177/2045125320980573
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.